Influence of Cyclooxygenase-2 (COX-2) gene promoter-1195 and allograft inflammatory factor-1 (AIF-1) polymorphisms on allograft outcome in Hispanic kidney transplant recipients

Human Immunology

Volumn 74, Issue 10, 2013, Pages 1386-1391

  Vu, Don ^a,b,c   Tellez Corrales, Eglis ^d   Shah, Tariq ^b,c,e,f   Hutchinson, Ian ^a,e   Min, David I ^b,c  

^a National Institute of Transplantation Los Angeles   (United States)

^b ST VINCENT MEDICAL CENTER   (United States)

^c WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^d NOVA SOUTHEASTERN UNIVERSITY   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f Transplant Research Institute   (United States)

Author keywords

AIF 1; AR; COX 2; SNP

Indexed keywords

ALLOGRAFT INFLAMMATORY FACTOR 1; CYCLOOXYGENASE 2; CYCLOSPORIN; CYSTEINE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; THREONINE;

ADULT; ARTICLE; CONTROLLED STUDY; ETHNICITY; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GRAFT RECIPIENT; GRAFT SURVIVAL; HISPANIC; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRON; KIDNEY ALLOGRAFT ACUTE REJECTION; KIDNEY ALLOGRAFT REJECTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROMOTER REGION; RENAL REPLACEMENT THERAPY; SINGLE NUCLEOTIDE POLYMORPHISM; SURGICAL PATIENT; SURGICAL RISK;

ACUTE REJECTION; AIF-1; ALLOGRAFT INFLAMMATORY FACTOR-1; AR; COX-2; CYCLOOXYGENASE-2; SINGLE NUCLEOTIDE POLYMORPHISM; SNP;

ADULT; ALLELES; ALLOGRAFTS; CYCLOOXYGENASE 2; DNA-BINDING PROTEINS; FEMALE; GENE FREQUENCY; GENOTYPE; GRAFT REJECTION; GRAFT SURVIVAL; HISPANIC AMERICANS; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; ODDS RATIO; PATIENT OUTCOME ASSESSMENT; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS, GENETIC;

EID: 84883800439     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2013.06.017     Document Type: Article

References (32)

1. 2008 Annual report of the US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant data 1998-2007. US Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, MD, USA 2008.
2. Nankivell B.J., Fenton-Lee C.A., Kuypers D.R., Cheung E., Allen R.D., O'Connell P.J., et al. Effect of histological damage on long term kidney transplant outcome. Transplantation 2001, 71:515-523.
3. Sijpkens Y.W., Joosten S.A., Wong M.C., Dekker F.W., Benediktsson H., Bajema I.M., et al. Chronic rejection with or without transplant vasculopathy. Clin Transplant 2003, 17:163-170.
4. Autieri M.V., Kelemen S., Thomas B.A., Feller E.D., Goldman B.I., Eisen H.J. Allograft inflammatory factor-1 expression correlates with cardiac rejection and development of cardiac allograft vasculopathy. Circulation 2002, 22(106):2218-2223.
5. Nagakawa Y., Nomoto S., Kato Y., Montgomery R.A., Williams G.M., Klein A.S., et al. Over-expression of AIF-1 in liver allografts and peripheral blood correlates with acute rejection after transplantation in rats. Am J Transplant 2004, 4:1949-1957.
6. Kuschel R., Deininger M.H., Meyermann R., Bornemann A., Yablonka-Reuveni Z., Schluesener H.J. Allograft inflammatory factor-1 is expressed by marcophages in injured skeletal muscle and abrogates proliferation and differntiation of satellite cells. J Neurophtol Exp Neurol 2000, 59:323-332.
7. Deininger M.H., Meyermann R., Schluesener H.J. The allograft inflammatory factor-1 family of proteins. FEBS Lett 2002, 514:115-121.
8. Grimm P.C., Mckenna R., Nichkerson P., Russell M.E., Gough J., Gospodarek E., et al. Clinical rejection is distinguished from subclinical rejection by increased infiltration by a population of activated macrophages. J Am Soc Nephrol 1999, 10:1582-1589.
9. Tsubata Y., Sakatsume M. Ogawa, Alchi B, Kaneko Y, Kuroda T, Kawachi H, Narita I, Yamamoto T, Geiyo F. Expression of allograft inflammatory factor-1 in kidneys: A novel molecular component of podocyte. Kidney Int 2006, 70:1948-1954.
10. Otieno F.G., Lopez A.M., Jimenez S.A., Gentiletti J., Artlett C.M. Allograft inflammatory factor-1 and tumor necrosis factor single nucleotide polymorphisms in systemic sclerosis. Tissue Antigens 2007, 69:583-591.
11. Alkassab F., Gourh P., Tan F.K., Gentiletti J., Artlett C.M. An allograft inflammatory factor 1 (AIF1) single nucleotide polymorphism (SNP) is associated with anticentromere antibody positive systemic sclerosis. Rheumatology 2007, 46:1248-1251.
12. Tiley S.L., Coffman T.M., Koller B.H. Mixed messages: Modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest 2001, 108:15-23.
13. Helliwell R.J., Adams L.F., Mitchell M.D. Prostaglandin synthases: recent developments and a novel hypothesis. Prostaglandins Leukot Essent Fatty Acids 2004, 70:101-103.
14. Cipollone F., Toniato E., Martinotti S., Fazia M., Iezzi A., Cuccurullo C., et al. MEZZETTI A; Identification of New Elements of Plaque Stability (INES) Study Group. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardical infarction and stroke. JAMA 2004, 291(18):2221-2228.
15. Szczeklik W., Sanak M., Szczeklk A. Functional effects and gender association of COX-2 gene polymorphism G-765C in bronchial asthma. J Allergy Clin Immunol 2004, 114:248-253.
16. Orbe J., Beloqui O., Rodriguez J.A., Belzunce M.S., Roncal C., Páramo J.A. Protective effect of the G-765C COX-2 polymorphism on subclinical atherosclerosis and inflammatory markers in asymptomatic subjects with cardiovascular risk factors. Clin Chm Acta 2006, 368:138-143.
17. Konheim Y.L., Wolford J.K. Association of a promoter variant in the inducible cyclooxygenase-2 gene (PTGS2) with type 2 diabetes mellitus in Pima Indians. Hum Genet 2003, 113:337-381.
18. Zhang X., Miao X., Tan W., Ning B., Liu Z., Hong Y., et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 2005, 129:565-576.
19. Dixon D.A. Regulation of Cox-2 expression in human cancers. Prog Exp Tumor Res 2003, 37:52-71.
20. Sakaki M., Makino R., Hiroishi K., Ueda K., Eguchi J., Hiraide A., et al. Cyclooxygenase-2 gene promoter polymorphisms affect susceptibility to hepatitis C virus infection and disease progression. Hepatol Res 2010, 40:1219-1226.
21. Rangel E.B., Moura L.A., Franco M.F., Pacheco-Silva A. Up-regulation of cyclooxygenase-2 during acute human renal allograft rejection. Clin Transplant 2005, 19:543-550.
22. Rangel E.B., Moura L.A., Franco M.F., Pacheco-Silva A. Up-regulation of cyclooxygenase-2 in different grades of acute human renal allograft during allograft rejection. Prostaglandins, Leukotrienes and Essential Fatty Acids 2007, 76:235-243.
23. Hoffmann U., Banas B., Krüger B., Pietrzyk M., Obed A., Segerer S., et al. Expression of cyclooxygenase-1 and cylooxygenase-2 in human renal allograft rejection-a prospective study. Transplant Int 2006, 19:203-212.
24. Courivaud C., Bamoulid J., Loupy A., Deschamps M., Ferrand C., D, Tiberghien Le COrre Influence of cyclooxygenase-2 (COX-2) gene promoter polymorphism -756 on graft loss after renal transplantation. Am J Transplant 2009, 9(12):2752-2757.
25. Utans U., Arceci R.J., Yamashita M.E., Russell M.E. Cloning and characterization of allograft inflammatory factor-1: a novel macrophage factor identified in rat cardiac allograft with chronic rejection. J Clin Invest 1995, 95:2954-2962.
26. Kelemen S.E., Autieri M.V. Expression of allograft inflammatory factor-1 in T-lymphocytes: a role in T-lymphocyte activation and proliferative arteriopathies. Am J Pathol 2005, 167:619-626.
27. Deininger M.H., Meyermann R., Schluesener H.J. The allograft inflammatory factor-1family of proteins. FEBS let 2002, 514:115-121.
28. Barker A.K., McDaniel D.O., Zhou X., He Z., Aru G., Thomas T., et al. Combined analysis of allograft inflammatory factor-1, interleukin-18, and Toll-like receptor expression and association with allograft rejection and coronary vasculopathy. Am Surg 2010, 76(8):872-878.
29. Nagakawa Y., Nomoto S., Kato Y., Montgomery R.A., Williams G.M., Klein A.S., et al. Over-expression of AIF-1 in liver allografts and peripheral blood correlates with acute rejection after transplantation in rats. Am J Transplant 2004, 4(12):1949-1957.
30. Autieri M.V., Kelemen S., Thomas B.A., Feller E.D., Goldman B.I., Eisen H.J. Allograft inflammatory factor-1 expression correlates with cardiac rejection and development of cardiac allograft vasculopathy. Circulation 2002, 22,106(17):2218-2223.
31. Utans U., Quist W.C., McManus B.M., Wilson J.E., Arceci R.J., Wallace A.F., et al. Allograft inflammatory factory-1. A cytokine-responsive macrophage molecule expressed in transplanted human hearts. Transplantation 1996, 61(9):1387-1392.
32. Tian Y., Jain S., Kelemen S.E. Autieri M.V. AIF-1 expression regulates endothelial cell activation, signal transduction and vasculogenesis. Am J Physiol Cell Physiol 2009, 296:256-266.